2,15-dibromo-3,3,14,14-tetramethylhexadecanedioic acid | 87272-32-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2,15-dibromo-3,3,14,14-tetramethylhexadecanedioic acid
• 英文别名: 2,15-dibromo-3,3,14,14-tetramethyl-hexadecane-1,16-dioic acid；2,15-Dibromo-3,3,14-,14-tetramethylhexadecane-1,16-dioic acid
• CAS: 87272-32-0
• 化学式: C₂₀H₃₆Br₂O₄
• 分子量: 500.311
• InChiKey: AXXUJNIHMQQIIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.4
• 重原子数：
  26
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,15-dibromo-3,3,14,14-tetramethylhexadecanedioic acid 在 sodium methylate 作用下， 以 甲醇 、 水 为溶剂， 以61%的产率得到2,15-dimethoxy-3,3,14,14-tetramethylhexadecanedioic acid
  参考文献：
  名称：

  Long-chain .alpha.,.omega.-dicarboxylic acids and derivatives thereof

  摘要：

  一种新的化合物类别已经发现在体内有效地阻断胆固醇和中性脂质合成，而不会对能量代谢产生不良影响，对于治疗肥胖、高脂血症和成人发病型糖尿病非常有用。这些活性化合物具有一般结构式##STR1## 或其体内可水解的羧基官能衍生物，其中R.sub.1和R.sub.2分别独立地代表未取代或取代的烃基或杂环烷基基团；X和Y各自独立地代表氢、可选择取代的较低烷基、卤素、氰基、羧基、较低烷氧羰基或氨基甲酰基；Q代表由8至14个碳原子组成的线性链的双基团，其中一个或多个碳原子可以被杂原子取代，该链可选择地被惰性取代基取代，其中一个或多个碳或杂原子链成员可选择地构成环结构的一部分。

  公开号：

  US04689344A1
• 作为产物：
  描述：

  2,15-dibromo-3,3,14,14-tetramethyl hexadecane-1,16-dioyl chloride 在 水 作用下， 反应 20.0h， 以60%的产率得到2,15-dibromo-3,3,14,14-tetramethylhexadecanedioic acid
  参考文献：
  名称：

  Synthesis and hypolipidemic and antidiabetogenic activities of .beta.,.beta.,.beta.',.beta.'-tetrasubstituted, long-chain dioic acids

  摘要：

  beta,beta,beta',beta'-Tetrasubstituted, long-chain dioic acids of the general formula HOOC-C(XY)-C(R2)-Q-C-(R2)-C(XY)-COOH have been synthesized and evaluated as hypotriglyceridemic-hypocholesterolemic agents in rats and as antidiabetogenic agents in ob/ob diabetic mice. The free carboxyl function of analogues of the series was mandatory for their hypolipidemic-antidiabetogenic effect while nonhydrolyzable diesters were inactive. Other structure-activity relationships were determined as a function of the overall chain length (C12-C22), alpha,alpha'-substitutions (X, Y = H, F, Cl, Br, OH, CN), beta, beta'-substitutions (R = CH3, C6H5), and core substitutions [Q = (CH2)10, (CH2)4CH = CH(CH2)4, 1,4-C6H10[(CH2)3]2, 1,4-C6H4[(CH2)3]2, 1,4-C6H4(CH = CHCH2)2, CH2(OCH2CH2)3OCH2)]. The most effective hypolipidemic-antidiabetogenic members of the series were alpha,alpha'-nonsubstituted, beta,beta'-methyl-substituted analogues of 14-18-carbon chains having either a saturated aliphatic core or a 1,4-bis(propenyl)benzene core in the cis/trans configuration. The hypotriglyceridemic rather than the hypocholesterolemic capacity of members of the series was found to correlate with their respective capacities as liver peroxisomal proliferators in rats.

  DOI：

  10.1021/jm00129a010

文献信息

• .alpha., .omega.-dicarboxylic acids and medicaments which contain these
  申请人：EPIS S.A.

  公开号：US04711896A1

  公开（公告）日：1987-12-08

  ##STR1## .alpha., .omega.-dicarboxylic acids having the general formula (I') in which: R.sub.1 and R.sub.2, which may be different or the same, represent a lower alkyl group which can be substituted by hydroxy, lower alkoxy, halogen or phenyl, the phenyl being capable of substitution one or several times by hydroxy, lower alkoxy, lower alkyl or halogen; a lower alkenyl or alkinyl group; a C.sub.3 -C.sub.7 -cyclo-alkyl group or a phenyl group possibly substituted by hydroxy, halogen, lower alkyl or lower alkoxy, and X and Y, which may be different or the same, represent hydrogen, lower alkyl, lower alkoxy, hydroxy, cyano, halogen, carboxyl, lower alkoxycarbonyl or carbamoyl, and Q represents non-ramified, saturated or unsaturated alkyl chain with 8-14 C atoms, which can be substituted, interrupted by hetero-atoms, and form part of a cyclic system, as well as their carboxylic acid derivatives in vivo, provided that when Q represents an unramified, saturated alkyl chain with 8-14 C atoms, and R.sub.1 and R.sub.2 represent methyl and Y represents hydrogen, X may not represent hydrogen, ethoxy-carbonyl, bromine, cyano or methyl, and if R.sub.1 and R.sub.2 represent methyl and X and Y hydrogen, then Q may not represent any formula (II) group. Process for their preparation and medicines containing these compounds, which have an anti-diabetic action and lower the level of lipids.

  本发明涉及具有下式（I'）的.alpha.，.omega.-二羧酸的化合物，其中：R.sub.1和R.sub.2，可以不同或相同，表示可以被羟基，低烷氧基，卤素或苯基替代的低烷基，该苯基能够被羟基，低烷氧基，低烷基或卤素替代一次或多次；低烯基或炔基；C.sub.3-C.sub.7-环烷基或可能被羟基，卤素，低烷基或低烷氧基替代的苯基，而X和Y，可以不同或相同，表示氢，低烷基，低烷氧基，羟基，氰基，卤素，羧基，低烷氧羰基或氨基，而Q表示非支链，饱和或不饱和的含8-14个碳原子的烷基链，可以被取代，被杂原子中断，并且成为环状系统的一部分，在体内的羧酸衍生物，前提是当Q表示一个具有8-14个碳原子的非支链，饱和烷基链，而R.sub.1和R.sub.2表示甲基，Y表示氢时，X不能表示氢，乙氧羰基，溴，氰或甲基，如果R.sub.1和R.sub.2表示甲基，而X和Y表示氢，则Q不能表示任何公式（II）的基团。制备这些化合物的方法和含有这些化合物的药物，具有降低血脂和抗糖尿病作用。
• Method of treating osteoarthritis
  申请人：——

  公开号：US20040048910A1

  公开（公告）日：2004-03-11

  This invention relates to combinations, compositions, and methods using or having a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound, or a pharmaceutically acceptable salt thereof, as an active component for preventing or treating osteoarthritis, preventing or inhibiting cartilage damage, preventing or treating rheumatoid arthritis, improving joint function, alleviating pain, and the like in a patient in need thereof.

  本发明涉及使用或含有取代的二烷基醚、取代的芳基-烷基醚、取代的二烷基硫醚、取代的二烷基酮或取代的烷基化合物，或其药学上可接受的盐作为活性成分，用于预防或治疗骨关节炎、预防或抑制软骨损伤、预防或治疗类风湿关节炎、改善关节功能、缓解疼痛等方面的组合物、组成物和方法，适用于需要治疗的患者。
• Method of lowering CRP and reducing systemic inflammation
  申请人：——

  公开号：US20040167229A1

  公开（公告）日：2004-08-26

  Disclosed are methods of lowering plasma CRP levels, reducing systemic inflammation, and inhibiting proinflammatory cytokine induced CRP production by administering an effective amount of a substituted dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, substituted-alkyl, or a pharmaceutically acceptable salt of the substituted dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl or a pharmaceutical composition comprising a substituted dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, substituted-alkyl.

  本发明涉及通过给予有效量的取代二烷基醚、取代烷基、取代芳基-烷基、取代二烷基硫醚、取代二烷基酮、取代烷基或其药学上可接受的盐，以及包含取代二烷基醚、取代烷基、取代芳基-烷基、取代二烷基硫醚、取代二烷基酮、取代烷基的药物组合物，来降低血浆CRP水平，减少全身性炎症，并抑制促炎细胞因子诱导的CRP产生的方法。
• Long-chain alpha, omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
  申请人：Epis S.A.

  公开号：EP0081930A1

  公开（公告）日：1983-06-22

  A novel class of compounds has been found to be effective in blocking cholesterol and neutral lipid synthesis n-vivo without adversely affecting energy metabolism. The active compounds have the general formula or in-vivo hydrolysable functional derivatives of the carboxylic groups thereof, wherein R1 and R2 each independently represents an unsubstituted or substituted hydrocarbyl or heterocyclyl radical; X and Y each independently represents hydrogen, optionally substituted lower alkyl, halogen, cyano, carboxy, lower alkoxycarbonyl or carbamoyl; and Q represents a diradical consisting of a linear chain of 8 to 14 carbon atoms, one or more of which may be replaced by heteroatoms, said chain being optionally substituted by inert substituents and one or more of said carbon or heteroatom chain members optionally forming part of a ring structure. The invention also provides pharmaceutical compositions comprising the aforementioned compounds of formula (I) for the treatment of obesity, hyperlipidemia and- maturity-onset diabetes.

  研究发现，一类新型化合物能有效阻止体内胆固醇和中性脂质的合成，而不会对能量代谢产生不利影响。这些活性化合物的通式为 或其羧基的体内可水解官能团衍生物，其中 R1 和 R2 各自独立地代表未取代或取代的烃基或杂环基； X和Y各自独立地代表氢、任选取代的低级烷基、卤素、氰基、羧基、低级烷氧基羰基或氨基甲酰基；以及 Q 代表由 8 至 14 个碳原子的线性链组成的二叉基，其中一个或多个碳原子可被杂原子取代，所述链可任选被惰性取代基取代，一个或多个所述碳或杂原子链成员可任选形成环状结构的一部分。 本发明还提供了包含上述式（I）化合物的药物组合物，用于治疗肥胖症、高脂血症和成熟期糖尿病。
• Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such
  申请人：Kowala C. Mark

  公开号：US20050004196A1

  公开（公告）日：2005-01-06

  Disclosed herein are pharmaceutical compositions including a dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, substituted-alkyl, or a pharmaceutically acceptable salt of said dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl, and a selective cyclooxygenase-2 (COX-2) inhibitor, or a pharmaceutically acceptable salt of said selective COX-2 inhibitor. Also disclosed are methods of using such pharmaceutical compositions for the treatment of inflammation and inflammation-associated diseases, inflammation and inflammation-associated disorders mediated by proinflammatory cytokines, and proinflammatory cytokine induced CRP production.

  本文公开了药物组合物，包括二烷基醚、取代的烷基、取代的芳基烷基、取代的二烷基硫醚、取代的二烷基酮、取代的烷基或所述二烷基醚、取代的烷基、取代的芳基烷基、取代的二烷基硫醚、取代的二烷基酮或取代的烷基的药学上可接受的盐，以及选择性环氧化酶-2（COX-2）抑制剂或所述选择性COX-2抑制剂的药学上可接受的盐。还公开了使用此类药物组合物治疗炎症和炎症相关疾病、由促炎细胞因子介导的炎症和炎症相关疾病以及促炎细胞因子诱导的 CRP 生成的方法。